Clinical Trials on Psoriasis Vulgaris in Belgium

Total 141 results

University Hospital, Ghent

Recruiting

Therapeutic Drug Monitoring of Tildrakizumab in Psoriasis Patients (BIOLOPTIM-TIL)

Psoriasis Vulgaris

Belgium
University Hospital, Ghent
University Ghent

Completed

Modified Intermittent Fasting in Psoriasis (MANGO)

Psoriasis | Psoriasis Vulgaris

Belgium
University Hospital, Ghent
Belgium Health Care Knowledge Centre

Not yet recruiting

Proactive TDM Versus Standard Use of Biologics in Psoriasis (HELIOS)

Psoriasis Vulgaris

Belgium
University Hospital, Ghent

Recruiting

Therapeutic Drug Monitoring of Risankizumab in Psoriasis Patients (BIOLOPTIM-RIS) (BIOLOPTIM-RIS)

Psoriasis Vulgaris

Belgium
University Hospital, Ghent
KU Leuven; University Ghent

Recruiting

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO) (BIOLOPTIM-BRO)

Psoriasis Vulgaris

Belgium
University Hospital, Ghent
KU Leuven; University Ghent

Completed

Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients (BIOLOPTIM-GUS)

Psoriasis Vulgaris

Belgium
University Hospital, Ghent
KU Leuven; University Ghent

Completed

Therapeutic Drug Monitoring of Ixekizumab in Psoriasis Patients (BIOLOPTIM-IXE)

Psoriasis Vulgaris

Belgium
University Hospital, Ghent
KU Leuven; University Ghent

Completed

Therapeutic Drug Monitoring of Secukinumab in Psoriasis Patients. (BIOLOPTIM-SEC)

Psoriasis Vulgaris

Belgium
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris

Psoriasis Vulgaris

Belgium, Canada, France, Germany, Netherlands, Spain, United Kingdom
University Hospital, Ghent
KU Leuven; University Ghent

Terminated

Dose Tapering Study of Adalimumab in Psoriasis

Psoriasis Vulgaris

Belgium
Radboud University Medical Center
University Hospital, Ghent; ZonMw: The Netherlands Organisation for Health... and other collaborators

Active, not recruiting

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio)

Psoriasis | Psoriasis Vulgaris

Netherlands, Belgium
Galderma R&D

Completed

Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis

Psoriasis Vulgaris

United States, Canada, Belgium, Germany, Italy
LEO Pharma

Terminated

Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab (COBRA)

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

Belgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
Cliniques universitaires Saint-Luc- Université...
Amgen

Completed

Molecular Effects of Apremilast in the Synovium of Psoriatic Arthritis Patients (MEAS)

Psoriatic Arthritis

Belgium
LEO Pharma

Recruiting

Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight (ADJUST)

Psoriasis Vulgaris

Belgium, Italy, Spain, Germany, Czechia, Greece, United Kingdom, France, Hungary, Poland, Netherlands
Cliniques universitaires Saint-Luc- Université...
University Hospital, Ghent; Janssen-Cilag International NV

Completed

TNF and IL23 Blocking Agents Gene Expression Ratios in the Psoriatic Arthritis Synovium_(TIGERS) Study (TIGERS)

Psoriatic Arthritis

Belgium
Pfizer

Completed

Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis (PROVE)

Arthritis, Psoriatic

Belgium
Pfizer

Completed

An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria (BEFLEX)

Plaque Psoriasis Patients

Belgium
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE VIVID)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
Galapagos NV

Completed

A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis (EQUATOR)

Psoriatic Arthritis

Estonia, Belgium, Bulgaria, Czechia, Poland, Spain, Ukraine
Eli Lilly and Company

Completed

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis (SPIRIT-P1)

Psoriasis, Arthritic

United States, Spain, Russian Federation, Belgium, Bulgaria, Canada, Czechia, Estonia, France, Japan, Mexico, Netherlands, Poland, Ukraine, United Kingdom
Galapagos NV

Terminated

An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.

Psoriatic Arthritis

Estonia, Belgium, Bulgaria, Czechia, Poland, Spain, Ukraine
University Hospital, Antwerp

Unknown

Studying the Skin Microbiome and the Potential of a Topical Probiotic Cream for Patients With Acne

Acne Vulgaris

Belgium
ACELYRIN Inc.

Completed

A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis

Psoriatic Arthritis

Poland, Hungary, Germany, Belgium, Czechia, Austria, Spain
University Hospital, Ghent
Novartis

Completed

Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris

Vitiligo Vulgaris

Belgium
Amgen

Completed

A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium (APOLO)

Arthritis, Psoriatic

Belgium
Amgen

Completed

Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis

Psoriatic Arthritis

Belgium, Canada, United Kingdom, Germany, Netherlands
LEO Pharma

Completed

Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis

Psoriasis of Scalp

France, Canada, Belgium, Denmark, Sweden
University Hospital, Ghent
KU Leuven

Completed

A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are Overtreated

Psoriasis

Belgium
Amgen

Completed

A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis (MOSAIC)

Psoriatic Arthritis

Spain, Belgium, Denmark, United States, Germany, Russian Federation, Austria, United Kingdom, Canada, Italy, Switzerland
Galderma R&D

Completed

An Open, Non-comparative Study of the Efficacy and Safety of Treatment of Acne Scars With Restylane Vital Lidocaine

Acne Scars

Belgium
Pfizer

Completed

Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice (PREPARE)

Psoriasis | Psoriatic Arthritis

Belgium, Denmark, France, Canada, Hungary, Germany, United States
Sun Pharmaceutical Industries Limited

Active, not recruiting

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Active Psoriatic Arthritis

United States, Australia, Czechia, Germany, India, Japan, Korea, Republic of, Poland, Spain
Pfizer

Recruiting

Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical Practice

Psoriatic Arthritis

Israel, France, Spain, Finland, Netherlands, Belgium, Denmark, Sweden
Amgen

Recruiting

Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis (PEAPOD)

Active Juvenile Psoriatic Arthritis

Spain, Turkey, Belgium, France, Greece, Italy, United Kingdom, Austria, Germany, Netherlands, Poland, Romania, Lithuania, South Africa, Portugal
Bristol-Myers Squibb

Terminated

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

Psoriatic Arthritis

Argentina, France, Italy, United States, Canada, Belgium, Netherlands, Australia, Germany, South Africa, Spain, Norway
Stiefel, a GSK Company

Completed

An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne

Acne

Belgium, Netherlands
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy (PENGUIN 2)

Psoriatic Arthritis

Korea, Republic of, United States, Australia, Belgium, Canada, Czechia, Hungary, Japan, Poland, Spain, Taiwan
University Hospital, Ghent
Novartis; Janssen, LP; Vlerick Business School; Scientific Research Foundation-Flanders

Recruiting

Value Based Healthcare in Psoriasis (IRIS)

Psoriasis

Belgium
Universitaire Ziekenhuizen KU Leuven

Recruiting

ProspectIve Cohort psoriASiS fOllow-up (PICASSO) (PICASSO)

Psoriasis

Belgium
University Hospital, Ghent

Completed

Therapeutic Drug Monitoring of Adalimumab in Psoriasis Patients

Psoriasis

Belgium
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis

Psoriasis of Scalp

Canada, Belgium, Finland, France, Germany, Netherlands, United Kingdom
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

Psoriatic Arthritis (PsA)

United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
Amgen

Completed

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

Psoriasis | Psoriatic Arthritis

United States, Canada, United Kingdom, Australia, Hungary, Belgium, Netherlands, Germany, Czechia, Estonia, Latvia
Novartis Pharmaceuticals

Completed

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA) (PDUS)

Psoriatic Arthritis

Germany, Netherlands, Spain, Argentina, Belgium, Colombia, Italy, United States, United Kingdom, Ireland, France, Mexico, Canada, Austria, Czechia, Hungary, Norway
Sun Pharmaceutical Industries Limited

Recruiting

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Active Psoriatic Arthritis

United States, Australia, Czechia, Estonia, Korea, Republic of, Poland, Slovakia, Spain, Taiwan, Germany, Italy, India, Canada
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis (FUTURE 2)

Psoriatic Arthritis

Germany, United Kingdom, Belgium, United States, Australia, Thailand, Russian Federation, Czechia, Canada, Poland, Puerto Rico
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) (FUTURE 1)

Psoriatic Arthritis

Germany, United Kingdom, United States, Belgium, Philippines, Singapore, Thailand, Brazil, Czech Republic, Italy, Argentina, Israel, Russian Federation, Bulgaria, Romania, Australia, Canada, Poland, Slovakia
Novartis Pharmaceuticals

Completed

Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis (FUTURE 1 ext)

Psoriatic Arthritis

United Kingdom, Belgium, Germany, Thailand, Israel, United States, Philippines, Singapore, Italy, Argentina, Russian Federation, Bulgaria, Czechia, Australia, Canada, Poland, Brazil, Slovakia
UCB Biopharma SRL

Completed

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE OPTIMAL)

Psoriatic Arthritis

United States, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Russian Federation, Spain, United Kingdom

Clinical Trials on Psoriasis Vulgaris in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations